key: cord-1051859-yvly0yf5
authors: McNaughton, A. L.; Paton, R. S.; Edmans, M.; Youngs, J.; Wellens, J.; Phalora, P.; Fyfe, A.; Belij-Rammerstorfer, S.; Bolton, J.; Ball, J.; Carnell, G.; Dejnirattisai, W.; Dold, C.; Eyre, D. W.; Hopkins, P.; Howarth, A.; Kooblall, K.; Klim, H.; Leaver, S.; Lee, L.; Lopez-Camacho, C.; Lumley, S. F.; Macallan, D.; Mentzer, A. J.; Provine, N.; Ratcliff, J.; Slon-Compos, J.; Skelly, D.; Stolle, L.; Supasa, P.; Temperton, N.; Walker, C.; Wang, B.; Wyncoll, D.; OPTIC consortium,; SNBTS consortium,; Simmonds, P.; Lambe, T.; Baillie, K.; Semple, M. G.; Openshaw, P. I.; ISARIC4C consortium,; Obol,
title: Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
date: 2021-05-07
journal: nan
DOI: 10.1101/2021.05.04.21256571
sha: 811cb9a4132f538664df37f736808022d6f74355
doc_id: 1051859
cord_uid: yvly0yf5

It is unclear whether prior endemic coronavirus infections affect COVID-19 severity. Here, we show that in cases of fatal COVID-19, antibody responses to the SARS-COV-2 spike are directed against epitopes shared with endemic beta-coronaviruses in the S2 subunit of the SARS-CoV-2 spike protein. This immune response is associated with the compromised production of a de novo SARS-CoV-2 spike response among individuals with fatal COVID-19 outcomes.

Four human coronaviruses (HCoV) are currently considered endemic worldwide. These include two beta--coronaviruses, HCoV--OC43 and HCoV--HKU1, as well as two alpha-coronaviruses, HCoV--229E and HCoV--NL63. Infection by these viruses in the majority of people causes a mild respiratory illness (1) . Over the past two decades, two further beta--coronaviruses have also emerged, SARS--CoV--1 and MERS--CoV. Whilst both viruses 95 have been more pathogenic than endemic coronaviruses, their transmission and subsequent spread has remained limited (2) . In 2019 a fifth beta--coronavirus, SARS--CoV--2, emerged which has led to a pandemic with over 100 million cases and upwards of 3 million deaths confirmed to date (3) . Several studies have shown that prior infection with other HCoVs induces both cross--reactive antibody and T--cell cross--100 reactive responses to SARS--CoV--2 (4-7). However, the influence of prior HCoV exposure on COVID--19 severity and clinical outcome remains unclear (8).

The spike protein of SARS--CoV--2, which is the primary vaccine target, consists of the S1 and S2 subunits (9,10). The S1 subunit contains a more variable receptor--binding 105 domain (RBD), which mediates viral entry during the infection process via interaction with the angiotensin--converting enzyme 2 (ACE2) receptor. Antibodies targeting the RBD can be neutralising and have been shown to correlate with protection (11) . HCoV induced antibody responses do not appear to cross--react with the SARS--CoV--2 RBD (9,12), or at least do so infrequently (10). In contrast, it has previously been reported by 110 several studies that antibodies induced by prior HCoV infections cross--react with the SARS--CoV--2 S2 subunit (7,8,9,10).

Cross--reactive T--cell responses have also been reported to be present in many individuals (5, 7, 16, 17) , which may have been induced by HCoV infection. These studies 115 found CD4+ and CD8+ T cells reactive to SARS--CoV--2 spike peptide pools in blood samples from individuals unexposed to SARS--CoV--2 (5, 7, 16) . This indicates that prior exposure to HCoVs could confer a cross--reactive T--cell response in a subset of the population and could potentially affect COVID--19 severity (18) .

In this study, to determine if prior infection by HCoVs is associated with differences in COVID--19 severity, we retrospectively tested samples from individuals who previously had qRT--PCR--confirmed asymptomatic infection, as well as patients admitted to ICU with severe COVID--19, half of whom died.

We also analysed two large cohorts with SARS--CoV--2 neutralising antibodies obtained from UK seroprevalence studies: one containing sera from blood donors and the other sera collected from pregnant women sampled <14 weeks' gestation (19, 20) . These two cohorts did not have a precise clinical definition of SARS--CoV--2 infection severity. As a third control cohort, we included SARS--CoV--2 seronegative individuals from the same 130 blood donor seroprevalence study (20) . Further details of the cohorts can be found in Table 1 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We used an MSD V-PLEX assay to quantify total antibody responses to the SARS-CoV-2 nucleocapsid (N), the RBD, N-terminal domains (NTD) of the spike, the SARS-CoV-2 fulllength spike as well as the spike proteins of the four HCoVs and SARS-CoV-1. In-house indirect ELISAs were also developed for the SARS-CoV-2 RBD and full-length spike, in addition to the full-length alpha-and beta-HCoV spike proteins to confirm the results 180 produced by the V-PLEX assay. Both the MSD assay and in-house ELISAs correlated well ( Figure S1 ).

We found that the antibody titres to the SARS-CoV-2 spike and nucleocapsid generally correlated with increasing COVID-19 severity ( Figure 1 ). However, individuals with fatal 185 COVID-19 consistently exhibited lower titres to SARS-CoV-2 spike antigens; the SARS-CoV-2 RBD (p = 0.01), and NTD (p = 0.02) of the spike as well as the full length spike (p = 0.02) were higher in the non-fatal ICU cohort compared to the fatal ICU cohort (Figure 1a ).

In contrast, no difference in reactivity to the SARS-CoV-2 nucleocapsid protein was identified (p = 0.99).

To test responses to the S2 subunit of the SARs-CoV-2 spike protein we developed an S2 indirect ELISA. In contrast to the other SARS-CoV-2 spike antigens measured by both the V-PLEX assay and in-house ELISA, there was no difference in SARS-CoV-2 S2 ELISA responses the ICU fatal and non-fatal cohorts (Figure 2a: p = 0.99).

Fatal COVID-19 outcomes were not associated with lower neutralising antibody titres as measured using a pseudotyped SARS-CoV-2 virus microneutralisation assay (Figure 2b , p = 0.96). An R-PLEX ACE2 competition assay using the full-length spike and RBD as antigens was run to confirm this result. The R-PLEX assay showed no significant difference in binding 200 inhibition between ACE2 and the spike protein (p = 0.83). However, there was significantly lower inhibition of binding between the RBD and ACE2 in the R-PLEX for individuals with fatal outcomes (Figure 2c ; p = 0.02). 205 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We compared responses to HCoV spike antigens in the cohorts to determine how they correlated with COVID-19 severity. The fold-change in HCoV response was calculated by 210 dividing the antibody titres of each sample by the average titre in the SARS-CoV-2 seronegative blood donor cohort using the data show in Figure 1 (Figure 2a and Table S1 , 18 ).

All cohorts previously infected with SARS-CoV-2 showed increased responses to the 215 endemic beta-HCoV spike proteins relative to the unexposed background cohort (Figure 2a) , suggesting that infection with SARS-CoV-2 induces increased cross-reactive responses, as reported elsewhere (10, 12) . No such trend was observed between the cohorts for antibody responses to alpha-HCoV spike proteins, which were comparable between all cohorts, irrespective of SARS-CoV-2 infection status.

We found that the increased reactivity to the beta-HCoV spike proteins was also broadly associated with COVID-19 severity. The response to the HCoV-OC43 spike antigen was significantly larger for those admitted to ICU than either the infected (p = 2.93×10 -6 ) or asymptomatic groups (p = 3.73×10 -4 ; Figure 3a ). Similar increases were observed for the 225 beta-HCoV HKU1 spike protein, although these were smaller in magnitude in comparison to those associated with the HCoV-OC43 spike protein ( Figure 3a ). As with antibody responses to the HCoV-OC43 spike protein, those who had to be treated in ICU had statistically significantly higher HCoV-HKU1 spike responses compared to asymptomatic (p = 9.2×10 -4 ) and infected (p = 2.85×10 -7 ) groups. However, significantly higher responses to the HCoV-230 HKU1 spike protein were not observed for those who were asymptomatic (p = 0.19) There was no significantly higher response to either the HCoV-OC43 (p = 0.07) or HCoV-HKU1 (p = 0.26) spike proteins in the SARS-CoV-2 antibody positive blood donor cohort.

There was no comparative increase in antibody responses to alpha-HCoV (HCoV-NL63 and 235 HCoV-229E) spike proteins following SARS-CoV-2 infection in either the blood donor or asymptomatic cohorts. However, smaller increases in responses to alpha-HCoV spike protein were detected in the fatal/non-fatal ICU cohorts and the antenatal control group. For all endemic coronaviruses, the antenatal cohort had an elevated HCoV response in comparison to blood donors, which could be not explained by biases in age or sex, but we suggest these 240 trends could be due to environmental differences ( Figure 1; Figure 3a ). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 245 We then analysed how the SARS--CoV--2 antibody response correlated with the antibody response to beta--HCoV spike proteins. We calculated the Spearman's rank correlation coefficients for all pairs of antigens from the V--PLEX assay, split by cohort (Figure  3b) . In fatal cases of COVID--19, responses to shared epitopes in the HCoV--OC43 spike protein increased in magnitude to a greater extent than those in the HCoV--HKU1 spike protein ( Figure 3 ). To identify the location of the beta--HCoV response causing the correlation, we subdivided the HCoV--OC43 spike protein into the NTD (aa 1--419) as well as the S1

(aa 1--794) and S2 (aa 766--1304) subunits of the spike protein ( Figure 4a ).

In response to both fatal and non--fatal SARS--CoV--2 infection, there was an increase in response to all the HCoV--OC43 spike domains analysed, although the response to the S2 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256571 doi: medRxiv preprint subunit was considerably greater, indicating that the majority of shared SARS--CoV--2 and beta--HCoV epitopes reside in the S2 subunit.

There were no significant differences in the fold--change of responses to these specific regions between ICU patients with non--fatal and fatal COVID--19 outcomes (Figure  3b ).

There were median fold--increases of 6.93 (p = 1×10 --3 ), 2.48 (p = 4×10 --3 ), 31.4 (p = 2.×10 --18 ) increases to the NTD, S1 and S2 HCoV--OC43 spike domains, respectively, across the 285 fatal and non--fatal ICU cohorts in comparison to the blood donor control group.

We fitted a linear regression between the log--concentration of response between the HCoV--OC43 responses (NTD, S1, S2 and nucelocapsid) and either the SARS--CoV--2 full-length spike protein or nucleocapsid ( Figure  4b ). In those individuals with fatal COVID-- (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256571 doi: medRxiv preprint appears not to be linked with the responses to shared SARS--CoV--2/beta--HCoV epitopes, unlike that of the SARS--CoV--2 spike protein.

Our study shows that a dominant immune response targeting shared beta--coronavirus epitopes in the S2 subunit of the spike protein is associated with fatal COVID--19 disease.

To date, this is the first study to associate previous exposure to HCoVs directly with COVID--19 clinical outcomes.

Our results are in line with previous work (22) showing higher neutralising antibody titres and increased antibody levels to a range of beta--coronavirus antigens in patients with severe COVID--19. However, in contrast to those studies, we found that titres were significantly lower among patients with a fatal COVID--19 outcome. There was also a strong correlation in the cohort with a fatal COVID--19 outcome between antibody 330 responses to SARS--CoV--2 spike and nucleocapsid, and antibody responses to both HCoV--HKU1 and HCoV--OC43 spike proteins. This correlation was shown to be due to preferential targeting of the HCoV--OC43 S2 subunit, but not the HCoV--OC43 NTD or S1 subunit ( Figure 3 ; 9,10).

These observations suggest that individuals with fatal COVID--19 outcomes are failing to mount the same level of de novo immune responses to novel epitopes specific to the SARS--CoV--2 spike as those who had non--fatal outcomes. This could reflect an immune response that is influenced by past exposure to endemic beta--coronaviruses, likely due (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. 

This study is further limited by the absence of longitudinal samples, which might help determine why some individuals mount a targeted S2 response whilst others do not. Our

HCoV--OC43 nucleocapsid protein assay shows this is not due to recent HCoV--OC43 infection, which would have shown increased responses to HCoV--OC43 nucleocapsid 380 relative to the negative blood donor controls (Figure  3c ). The correlation between fatal COVID--19 and the observed targeted antibody response is likely due to an individual's past history of infection with HCoV--OC43/--HKU1. However, whether the key All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Ethical approval was obtained for the Scottish National Blood Transfusion Service Researchers working with the samples in the laboratory were blinded to the clinical outcomes of the ICU patients during testing. None of the study subjects received convalescent plasma therapy. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. The positive reference standard was used on each plate to produce a standard curve. A monoclonal antibody standard was used for the RBD/spike ELISAs. Pooled HCoV highly 550 reactive sera were used as a standard for the HCoV spike ELISAs.

Expressed in Provider Reference (if appropriate)

HCoV--OC43 spike Insect cells Sino Biological

HCoV--229E spike Insect cells Sino Biological All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. A 7--point calibration curve of the standards was prepared using Diluent 100. Diluent 100 was used as a negative control. An additional three positive controls provided with 575 the kit were also run on every plate. All standards and controls were run in duplicate.

Data from the assay was analysed using MSD Discovery Workbench software, which averaged all the duplicates, generated and fitted all the data to standard curves.

The ability of antibodies present in serum/plasma to inhibit the binding of angiotensin-converting enzyme 2 (ACE2) to the SARS--CoV full--length spike proteins and RBD domains was assessed using the COVID--19 ACE2 competition assay (MSD, USA). The assay can be used to estimate the neutralising activity of the antibodies present in the 585 samples.

Pre--coated plates were incubated at RT with Blocker A solution for at least 30 minutes whilst being shaken at 500--700 rpm. Serum or plasma was diluted in Diluent 100 at dilutions of 1:10 to 1:100 and samples were added to the plates in duplicate. Plates were 590 incubated for 1 hour at RT, whilst being shaken at 500--700 rpm throughout. A 1x All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256571 doi: medRxiv preprint working concentration of the SULFO--TAG ACE2 detect was prepared in Diluent 100.

After incubation with the samples, the plates were washed x3 with f 1x MSD Wash buffer. Prepared SULFO--TAG ACE2 solution was added to the plates, which were incubated at RT for a further 1 hour, whilst being shaken. Plates were then washed x3 595 with 1X MSD Wash buffer. To read the assay results, MSD GOLD Read Buffer B (provided ready to use) was added to the plate. Plates were read immediately after adding the buffer on a MESO QuickPlex SQ 120 (MSD, USA)

A 7--point calibration curve of the standards was prepared using Diluent 100. Diluent 600 100 was used as a negative control. All standards were run in duplicate. Data from the assay was analysed using MSD Discovery Workbench software, which averaged all the duplicates, generated and fitted all the data to standard curves.

A lentivirus--based pseudotyped virus system was used to display the SARS--CoV--2 spike protein on its surface using a synthetic codon optimised SARS--CoV--2 expression construct (NCBI reference sequence: YP_009724390.1).

Target cells were transfected 24 hours prior to assay setup with 2.75 ug of ACE2 expression plasmid and 250 ng of TPRSSM2 expression plasmid (20).

Over dispersed variables were transformed onto the logarithmic scale (base 10) for between group comparisons for V--PLEX platform concentrations, ELISA optical density and neutralising titres. Unless otherwise specified, a t--test assuming unequal variances was used to test for differences in the mean responses; values were analysed on the logarithmic (base 10) scale unless otherwise stated. A Holm correction was applied to p--620 values for multiple comparisons. In cases where a fold change or ratio is calculated, the log--scale group means can be compared to zero using a t--test to determine if the group differs from equal concentrations of antigens. For non--normal variables that do not meet the assumptions of normality -even if transformed -a Dunn's test was used instead.

Reported correlations are Spearman's rank, as the measure is non--parametric and 625 robust to transformation. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256571 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Samples were tested using a SARS-CoV-2 pseudotype microneutralisation assay. 730

Neutralisation titres were higher in the ICU cohorts than the blood donor, antenatal and asymptomatic groups, but there was no significant difference based on clinical outcomes of ICU stay (p = 0.99). c. ACE2 inhibition assay results. Samples were also analysed with an R-PLEX ACE2 inhibition assay (MSD). The level of ACE2 binding inhibition was not statistically significant for the spike, but the fatal ICU 735 cohort shows statistically lower ACE2-RBD binding inhibition in comparison to the non-fatal ICU cohort (p = 0.02).

740 745 750 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256571 doi: medRxiv preprint

a. Mean fold-change of antibodies to endemic coronaviruses. Antibodies to endemic beta-coronaviruses are boosted by SARS-CoV-2 infection and broadly correlate with COVID-19 severity. The mean fold-change to each spike protein was determined by dividing the average response to each antigen by responses in the background blood donor group (Table 1) . Broad classifications of COVID-19 clinical 765

presentations are given on the x-axis, with colour denoting sub-groups. A larger foldchange in OC43 and HCoV-HKU1 responses was observed in the ICU cohort relative to the blood donor, antenatal and asymptomatic groups, but not between infected and asymptomatic cohorts. The same increases were not observed for alphacoronaviruses. There were no significant differences observed in the mean fold 770 changes between the fatal and non-fatal ICU cohorts for any endemic HCoV. The data in this figure were generated using the ELISA-based MSD V-PLEX assay b.

Spearman's rank correlations (ρ) are shown for each pair of antigens, split by sample group. There is a positive correlation between all SARS-CoV-2 antigens in all but the 775 background blood donor group. Significant correlations are found between SARS-CoV-2 epitopes and endemic beta-HCoVs (OC43 and HCoV-HKU1) in the positive blood donor, antenatal and fatal ICU groups; these correlations are absent in the asymptomatic and non-fatal ICU groups. The correlation between endemic beta-HCoVs and SARS-CoV-2 epitopes are considerably weaker in the larger positive 780 blood donor and antenatal cohorts than in the fatal ICU samples. c. and d. groups with a clinical definition of COVID-19 severity (asymptomatic, non-fatal and fatal, across panel rows). The best fit line is shown in blue with 95% confidence intervals in grey; the dotted grey line denotes a 1:1 response to both antigens. There is a strong positive association between SARS-CoV-2 Spike/RBD and the endemic coronaviruses in the fatal ICU patients that is absent in the asymptomatic and non-790 fatal ICU patients.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. that this is a shared antibody target among the endemic beta-coronaviruses. 820 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256571 doi: medRxiv preprint Figure S1 : Correlation of MSD VPLEX and ELISA data. The correlation of results across the two assays for the SARS--CoV--2 full--length spike and RBD domains, along with 825 endemic coronavirus spike antigens is shown, with Spearman Rank correlations .

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256571 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256571 doi: medRxiv preprint Figure S4 : Responses categorised by age in the different groups.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256571 doi: medRxiv preprint Figure S5 : Responses categorised by sex in the different groups.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256571 doi: medRxiv preprint

Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real--time PCR method

COVID--19, SARS and MERS: are they closely related? Clinical Microbiology and Infection

Early transmission dynamics in

of novel coronavirus--infected pneumonia

Low avidity CD4+ T cell responses to SARS--CoV--2 in unexposed individuals and humans with severe COVID--19

Selective and cross--reactive SARS--CoV--2 T cell epitopes in unexposed humans

Seasonal human coronavirus antibodies are boosted upon SARS--CoV--2 infection but not associated with protection

Neutralizing antibodies correlate with protection from SARS--CoV--2 in humans 425 during a fishery vessel outbreak with a high attack rate

antigens in an age stratified cross--sectional 430 serosurvey in a large tertiary hospital in The Netherlands

Pre--existing and de novo humoral immunity to SARS--CoV--2 in humans

Severe COVID--19 patients display a back boost of seasonal coronavirus--specific antibodies

Antibody Immunological Imprinting on COVID--19 Patients. medRxiv

Phenotype and kinetics of SARS--CoV--2--specific T cells in COVID--19 patients with acute respiratory distress syndrome

T cell assays differentiate clinical and subclinical SARS--CoV--2 infections from cross--reactive antiviral responses

Cross--reactive T cells. Nature Medicine. 2020

antibody prevalence, titres and neutralising activity in an antenatal cohort

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 860 S6: Days from post--symptomatic and entry to ICU in the fatal and non--fatal groups

We would like to express our gratitude and acknowledge the contribution of the staff at Oxford University Hospitals NHS Foundation Trust, Scottish National Blood Transfusion Service and St George's University Hospitals NHS Foundation Trust (London) who were